

Supplemental Table 1. Subsequent neoplasms reported after HCT

Subsequent Neoplasm	TBI	Chemotherapy
Other leukemia	0	1
Genitourinary malignancy	0	1
Lung cancer	0	1
Melanoma	1	0
Other skin malignancy	3	4
Oropharyngeal cancer	2	1
Sarcoma	2	0
Not confirmed by path report: Genitourinary malignancy; Oropharyngeal cancer, TBI (N=1); Other leukemia; Other skin malignancy, TBI (N=1), non-TBI (N=2)		
HCT, allogeneic hematopoietic cell transplantation; TBI, total body irradiation		

Supplemental Table 2. Cumulative incidence of late effects at 10 years after HCT by age

Late effect	<u>15-19 years</u>		<u>20-29 years</u>		<u>30-39 years</u>		P*
	N	Prob (95% CI)	N	Prob (95% CI)	N	Prob (95% CI)	
Subsequent neoplasm	127	0.8 (0-3.1)%	321	3.9 (1.2-8.1)%	370	4.5 (1.5-9)%	0.07
Avascular necrosis	120	4.7 (1.5-9.5)%	307	9.9 (6.5-13.9)%	363	6.9 (3.4-11.4)%	0.16
Cataracts	124	7.3 (1.6-16.6)%	316	9.3 (5.5-14.1)%	371	11.4 (7.2-16.4)%	0.63
Diabetes mellitus	105	1.9 (0.2-5.4)%	250	5.5 (2-10.6)%	299	4.4 (2-7.7)%	0.26
Hypothyroidism	115	16.7 (8.1-27.6)%	307	9.7 (6.3-13.8)%	362	8.9 (5.6-12.8)%	0.34
Gonadal dysfunction	112	3 (0.6-7.3)%	311	3.5 (1.2-6.8)%	365	3.3 (1.3-6.2)%	0.97
* P value for comparison of 15-19 years vs. 20-29 years vs. 30-39 years at 10 years							
HCT, allogeneic hematopoietic cell transplantation							

Supplemental Table 3. Causes of death among AYA survivors with subsequent neoplasms (N=16)

	N (%)
Subsequent neoplasm	16
Alive	9 (56)
Dead	7 (44)
Primary Disease	1
GVHD	1
Organ failure	1
Subsequent neoplasm	1
Other cause*	1
Unknown	2

AYA, adolescent and young adults; GVHD, graft-versus-host disease

Supplemental Table 4. Prevalence of non-malignant late effects in AYAs with AML surviving at least 1-year disease-free following ablative HCT

Late Effect	All Patients (N=826)	TBI (N=390)	Chemotherapy-only (N=436)
Gonadal dysfunction	61 (7%)	30 (8%)	31 (7%)
Avascular necrosis	48 (6%)	28 (7%)	20 (5%)
Cataracts	51 (6%)	42 (11%)	9 (2%)
Diabetes mellitus	20 (2%)	13 (3%)	7 (2%)
Hypothyroidism	18 (2%)	11 (3%)	7 (2%)
Dialysis	15 (2%)	12 (3%)	3 (<1%)
Stroke/seizures	12 (1%)	11 (3%)	1 (<1%)
Congestive heart failure	4 (<1%)	2 (<1%)	2 (<1%)
Myocardial infarct	4 (<1%)	1 (<1%)	3 (<1%)
Pancreatitis	4 (<1%)	4 (1%)	0
Number of late effects reported per patient*			
0	643 (78)	270 (69)	373 (86)
1	139 (17)	87 (22)	52 (12)
2+	40 (5)	29 (7)	11 (2)

* Only includes late effects listed in this table
 AYAs, adolescent and young adults; AML, acute myeloid leukemia; HCT, allogeneic hematopoietic cell transplantation; TBI, total body irradiation